Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease

Journal of Allergy and Clinical Immunology

Volumn 137, Issue 5, 2016, Pages 1585-1587.e4

  Hayashi, Hiroaki ^a,b   Mitsui, Chihiro ^a   Nakatani, Eiji ^c   Fukutomi, Yuma ^a   Kajiwara, Keiichi ^a   Watai, Kentaro ^a,d   Sekiya, Kiyoshi ^a   Tsuburai, Takahiro ^a   Akiyama, Kazuo ^a   Hasegawa, Yoshinori ^b   Taniguchi, Masami ^a  

^a SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^d JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

11 EPIPROSTAGLANDIN F2 ALPHA; BIOLOGICAL MARKER; CORTICOSTEROID; LEUKOTRIENE E4; OMALIZUMAB; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN D2; ANTIASTHMATIC AGENT; CYSTEINE; CYSTEINYL-LEUKOTRIENE; LEUKOTRIENE; PROSTAGLANDIN F2 ALPHA;

ADULT; ASPIRIN EXACERBATED RESPIRATORY DISEASE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; FEMALE; HUMAN; KIDNEY CONCENTRATING CAPACITY; LETTER; MALE; PRIORITY JOURNAL; CLINICAL TRIAL; MIDDLE AGED; TREATMENT OUTCOME; URINE;

ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA, ASPIRIN-INDUCED; BIOMARKERS; CYSTEINE; DINOPROST; FEMALE; HUMANS; LEUKOTRIENES; MALE; MIDDLE AGED; OMALIZUMAB; TREATMENT OUTCOME;

EID: 84964810705     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2015.09.034     Document Type: Article

References (15)

1. A.R. Fischer, M.A. Rosenberg, C.M. Lilly, J.C. Callery, P. Rubin, J. Cohn, and et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma J Allergy Clin Immunol 94 1994 1046 1056
2. P.E. Christie, P. Tagari, A.W. Ford-Hutchinson, S. Charlesson, P. Chee, J.P. Arm, and et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects Am Rev Respir Dis 143 1991 1025 1029
3. D.D. Stevenson, and A. Szczeklik Clinical and pathologic perspectives on aspirin sensitivity and asthma J Allergy Clin Immunol 118 2006 773 786 quiz 87-8
4. J.P. Rajan, N.E. Wineinger, D.D. Stevenson, and A.A. White Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature J Allergy Clin Immunol 135 2015 676 681.e1
5. S.T. Holgate New strategies with anti-IgE in allergic diseases World Allergy Organ J 7 2014 17
6. N.A. Hanania, S. Wenzel, K. Rosen, H.J. Hsieh, S. Mosesova, D.F. Choy, and et al. Exploring the effects of omalizumab in allergic asthma: An analysis of biomarkers in the EXTRA study Am J Respir Crit Care Med 187 2013 804 811
7. K.N. Cahill, J.C. Bensko, J.A. Boyce, T.M. Laidlaw, and D. Prostaglandin A dominant mediator of aspirin-exacerbated respiratory disease J Allergy Clin Immunol 135 2015 245 252
8. S.M. Nasser, R. Pfister, P.E. Christie, A.R. Sousa, J. Barker, M. Schmitz-Schumann, and et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects Am J Respir Crit Care Med 153 1996 90 96
9. N. Higashi, H. Mita, E. Ono, Y. Fukutomi, H. Yamaguchi, K. Kajiwara, and et al. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers J Allergy Clin Immunol 125 2010 1084 1091.e6
10. P. Gevaert, L. Calus, T. Van Zele, K. Blomme, N. De Ruyck, W. Bauters, and et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma J Allergy Clin Immunol 131 2013 110 116.e1
11. N. Higashi, M. Taniguchi, H. Mita, Y. Kawagishi, T. Ishii, A. Higashi, and et al. Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): involvement of chronic hyperplastic rhinosinusitis with nasal polyposis J Allergy Clin Immunol 113 2004 277 283
12. T.W. Chang, C. Chen, C.J. Lin, M. Metz, M.K. Church, and M. Maurer The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria J Allergy Clin Immunol 135 2015 337 342
13. W. Busse, J. Corren, B.Q. Lanier, M. McAlary, A. Fowler-Taylor, G.D. Cioppa, and et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma J Allergy Clin Immunol 108 2001 184 190
14. M. Humbert, R. Beasley, J. Ayres, R. Slavin, J. Hebert, J. Bousquet, and et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 60 2005 309 316
15. G.J. Braunstahl, C.W. Chen, R. Maykut, P. Georgiou, G. Peachey, and J. Bruce The experience registry: the 'real-world' effectiveness of omalizumab in allergic asthma Respir Med 107 2013 1141 1151